文献速递血栓与止血

体重指数对静脉血栓栓塞症临床结局的影响:GARFIELD-VTE研究启示

Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE.
PubMed 文献 · J Thromb Haemost · 2021-09-16

结果显示低体重患者全因死亡和大出血风险最高,超重和肥胖患者全因死亡风险低于正常体重者,而复发VTE在各组间相当。

要点

  • 低体重VTE患者全因死亡和大出血风险最高。
  • 超重和肥胖VTE患者全因死亡风险低于正常体重者。
  • 各组复发VTE风险相当。

核心结论

  • 低体重VTE患者死亡和大出血风险最高,肥胖VTE患者死亡风险低于正常体重者。

研究设计与样本

  • 按BMI分组:<18.5低体重(n=214)、18.5-24.9正常(n=2866)、25.0-29.9超重(n=3326)、≥30肥胖(n=3073)。

主要发现

  • 肥胖患者较正常BMI者更多为白人(77.4% vs. 57.9%)、门诊治疗(30.4% vs. 23.1%)及既往VTE史(17.5% vs. 11.7%)。
  • 活动性癌症与较低BMI相关:低体重30.4%、正常13.5%、超重9.4%、肥胖7.0%。
  • 超重和肥胖患者基线单纯肠外治疗比例(16.7%和14.4%)低于低体重和正常BMI者(30.8%和21.6%)。
  • 肥胖患者抗凝≥2年比例高于正常BMI者(52.3% vs. 37.7%)。
  • 24个月时,超重和肥胖患者全因死亡风险低于正常BMI者,校正风险比[95%CI]分别为0.75[0.63-0.89]和0.59[0.49-0.72]。

关键数值与推荐

  • 低体重患者较正常BMI者更常发生大出血(2.45[1.41-4.26])和全因死亡(1.90[1.43-2.53])。
  • 复发VTE在各BMI组间相当。

临床怎么用

  • 临床应关注低体重VTE患者的高死亡和大出血风险。
  • 肥胖VTE患者死亡风险较低,但需注意长期抗凝管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited information on the influence of body mass index (BMI) on clinical outcomes in patients with venous thromboembolism (VTE). OBJECTIVES: Investigate the influence of BMI on baseline characteristics, treatment patterns, and 24-month outcomes in VTE patients. METHODS: GARFIELD-VTE is a prospective, non-interventional study of 10 869 patients with objectively confirmed VTE. Patients were grouped according to BMI: <18.5 (underweight; n = 214); 18.5-24.9 (normal; n = 2866); 25.0-29.9 (overweight; n = 3326); ≥30 (obese; n = 3073). RESULTS: Compared with patients with a normal BMI, obese patients were more frequently Caucasian (77.4% vs. 57.9%), treated in the outpatient setting (30.4% vs. 23.1%), and had previous VTE (17.5% vs. 11.7%). Active cancer was associated with lower BMI (underweight: 30.4%, normal: 13.5%, overweight: 9.4%, obese: 7.0%). At baseline, overweight and obese patients less often received parenteral therapy alone (16.7% and 14.4%) compared with those with an underweight or normal BMI (30.8% and 21.6%). Obese patients more commonly remained on anticoagulants for ≥2-years compared to those with a normal BMI (52.3% vs. 37.7%). After 24-months, the risk of all-cause mortality was lower in overweight and obese patients than in those with normal BMI (adjusted hazard ratio [95% CI]; 0.75 [0.63-0.89] and 0.59 [0.49-0.72], respectively). Underweight patients more often experienced major bleeding (2.45 [1.41-4.26]) and all-cause mortality (1.90 [1.43-2.53]) than patients with a normal BMI. Recurrent VTE was comparable among groups. CONCLUSION: Underweight VTE patients have the highest risk of mortality and major bleeding. The risk of mortality in obese VTE patients is lower than that in VTE patients with a normal BMI.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Weitz JI, Farjat AE, Ageno W, et al. Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. J Thromb Haemost. 2021. PMID: 34487616. doi:10.1111/jth.15520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。